Thursday, September 26, 2019

Immunotherapy Drugs Market worth USD 201.52 Billion by 2021

Immunotherapy Drugs Market worth USD 201.52 Billion by 2021
The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).
Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

What is the future growth analysis of global Immunotherapy Drugs Market?

The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5%

What are key factors driving growth of global Immunotherapy Drugs Market?

Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. Rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.


What the growth opportunities are in Immunotherapy Drugs Market?


1. Untapped Emerging Markets
2. Immunotherapy to Replace Chemotherapy in Cancer Treatment

Know more, Download PDF Brochure Now:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755 

Global Market Segmentation:

In the current market scenario, there is a growing demand for immunotherapy drugs market. The market has been categorized based on the type of drugs, therapy area, end user, and region.

Based on the type of drugs, the market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines. The others segment comprises of oncolytic virus therapy, and T-cell therapy. Monoclonal antibodies segment is expected to account for the largest market share in the market, by type of drugs in 2016. On the other hand, checkpoint inhibitors segment is expected to be the fastest growing segment in the market, by type of drugs, in 2016.

Furthermore, based on therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer segment is further sub-segmented into solid tumors and malignant tumors. Among these segments, the cancer segment is expected to account for the largest market share in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

The others segment comprises of cardiovascular, and ophthalmic diseases. Based on type of end-users in the healthcare industry, the market is segmented into hospitals, clinics, and others. The others segment comprises of home healthcare centers, and nursing home facilities.

Get Your Queries Resolved From Subject Expert | Speak To Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137717755

Geographic Growth Analysis:



North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

Media Contact
Company Name: MarketsandMarkets
Contact Person: Mr. Shelly Singh
Email:Send Email
Phone: 1-888-600-6441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/industrial-coatings-market-746.html